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The polymyxin antibiotics colistin (polymyxin E) and polymyxin B became available in the 1950s and
thus did not undergo contemporary drug development procedures. Their clinical use has recently
resurged, assuming an important role as salvage therapy for otherwise untreatable gram-negative
S P E C I A L A R T I C L E
infections. Since their reintroduction into the clinic, significant confusion remains due to the existence
of several different conventions used to describe doses of the polymyxins, differences in their formula-
tions, outdated product information, and uncertainties about susceptibility testing that has led to lack of
clarity on how to optimally utilize and dose colistin and polymyxin B. We report consensus therapeutic
guidelines for agent selection and dosing of the polymyxin antibiotics for optimal use in adult patients,
as endorsed by the American College of Clinical Pharmacy (ACCP), Infectious Diseases Society of Amer-
ica (IDSA), International Society of Anti-Infective Pharmacology (ISAP), Society for Critical Care Medi-
cine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). The European Society for Clinical
Microbiology and Infectious Diseases (ESCMID) endorses this document as a consensus statement. The
overall conclusions in the document are endorsed by the European Committee on Antimicrobial Suscep-
tibility Testing (EUCAST). We established a diverse international expert panel to make therapeutic rec-
ommendations regarding the pharmacokinetic and pharmacodynamic properties of the drugs and
pharmacokinetic targets, polymyxin agent selection, dosing, dosage adjustment and monitoring of col-
istin and polymyxin B, use of polymyxin-based combination therapy, intrathecal therapy, inhalation ther-
apy, toxicity, and prevention of renal failure. The treatment guidelines provide the first ever consensus
recommendations for colistin and polymyxin B therapy that are intended to guide optimal clinical use.
KEY WORDS polymyxin B, colistin, dosing guidelines.
(Pharmacotherapy 2019;39(1):10–39) doi: 10.1002/phar.2209
This practice guideline provides consensus
recommendations pertaining to the clinical use
of the polymyxin antibiotics, colistin (polymyxin
E) and polymyxin B, for the treatment of bacte-
rial infections in adults. The polymyxin antibi-
otics became available clinically in the 1950s
and thus did not undergo contemporary drug
development procedures.1 Polymyxins have a
unique mechanism of action involving disrup-
tion of the outer membrane integrity of gram-
negative bacteria that in addition to providing
rapid bactericidal activity may enhance the activ-
ity of other antibiotic classes.1 Their clinical use
has recently resurged, and the polymyxins have
assumed an important role as salvage therapy for
otherwise untreatable gram-negative infections,
most notably multidrug-resistant (MDR) and
extensively drug-resistant (XDR) strains of Pseu-
domonas aeruginosa, Acinetobacter baumannii, and
Enterobacteriaceae.2
Since their reintroduction into the clinic in
the 1980s through today, significant confusion
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remains regarding polymyxin use due to differ-
ences in the formulations. Colistin is adminis-
tered as an inactive prodrug, colistimethate (also
known as colistin methanesulfonate [CMS]),
whereas polymyxin B is administered in its
active form. Also, different conventions are used
to describe dosing of the polymyxins, particu-
larly colistin; product information is outdated;
and uncertainties remain regarding susceptibility
testing.3, 4 Thus a lack of clarity remains about
how optimally to utilize and dose colistin and
polymyxin B.5, 6 Unfortunately, polymyxins are
highly nephrotoxic agents, and acute kidney
injury (AKI) occurs frequently with conven-
tional doses.7, 8 Given the narrow therapeutic
windows (low therapeutic indices) of polymyx-
ins, this guideline provides clinicians with a
practical framework for use in treating infec-
tions caused by MDR and XDR gram-negative
pathogens.
Methods
Consensus Panel Composition
The Consensus Panel was composed of inter-
national experts. They represent membership in
the endorsing organizations (American College
of Clinical Pharmacy [ACCP], the European
Society for Clinical Microbiology and Infectious
Diseases [ESCMID], the Infectious Diseases Soci-
ety of America [IDSA], International Society of
Anti-Infective Pharmacology [ISAP], Society of
Critical Care Medicine [SCCM], and the Society
of Infectious Diseases Pharmacists [SIDP]).
Consensus Development Based on Evidence
Consensus Panel members were assigned key
topics that contribute to current knowledge and
optimal utilization of the polymyxins. A draft
document addressing these areas that included
specific recommendations was reviewed and
approved by all panel members. The panel con-
ducted face-to-face meetings and teleconferences
to complete the guideline work. The purpose of
the meetings and teleconferences was to deter-
mine and discuss the clinical questions to be
addressed, assign topics for review and writing
of the initial draft, and develop recommenda-
tions. The entire panel reviewed all sections.
After review by members of the ACCP, ESCMID,
IDSA, SCCM, ISAP, and SIDP, the panel
reviewed the submitted comments and recom-
mendations. After careful discussion and
consideration of these suggestions, the document
was revised and circulated among the panel and
supporting societies for final approval.
Literature Review and Analysis
The recommendations in this guideline were
developed following a review of studies pub-
lished before December 31, 2018, in English.
Studies were identified through Library of
Congress, LISTA (Library, Information Science
& Technology Abstracts [EBSCO]), and PubMed
database searches with no date restrictions using
Medical Subject Headings. Examples of key-
words used to conduct literature searches were
polymyxin, colistin, polymyxin B, nephrotoxicity,
pharmacokinetics, pharmacodynamics, area under
the curve, toxicodynamics, resistance, carbapenem,
A. baumannii, P. aeruginosa, and Klebsiella pneu-
moniae.
Process Overview
To evaluate evidence, the panel followed a
process consistent with other contemporary
guidelines. The process for evaluation was based
on the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE)
system, a newly created system for grading the
quality of evidence and strength of recommenda-
tions for health care.9 Some topics were deter-
mined to be ungradable such as those that
involved nonclinical evidence (such as recom-
mendations for in vitro minimum inhibitory
concentration [MIC] breakpoints) and thus were
not evaluated according to the GRADE criteria.
Some recommendations were labeled as best
practice recommendations, particularly in sce-
narios where the recommendations lack suffi-
cient randomized controlled trial (RCT)
evidence. Panel members were divided into
groups consisting of a primary lead author and
coauthors for each section. Each author was
asked to review the literature, evaluate the evi-
dence, develop and determine the strength of
recommendations, and provide an evidence sum-
mary supporting each recommendation. The
panel reviewed all recommendations, the
assigned strength of the recommendations, and
quality of evidence. Discrepancies were dis-
cussed and resolved. We acknowledge this as a
potential limitation. Similar to other guidelines,
some of the evidence used to establish the rec-
ommendations was published by the authors
writing each section.
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Clinical Questions and Recommendations
Susceptibility and Pharmacokinetics/
Pharmacodynamics
I. How Should Susceptibility Be Tested, and What
Are the Minimum Inhibitory Concentration Break-
points for the Polymyxins to Guide Therapy?
Recommendation. R1: The joint European Com-
mittee on Antimicrobial Susceptibility Testing
(EUCAST) and Clinical and Laboratory Stan-
dards Institute (CLSI) polymyxin breakpoint
working group recommended that standard
broth microdilution ISO-74 2077610 be used as
the reference method for the MIC testing of col-
istin and be performed with cation-adjusted
Mueller Hinton broth, with sulfate salts of col-
istin in plain polystyrene trays without additives
such as polysorbate-80.11, 12 Sulphate salts of
polymyxins must be used (the methanesulfonate
derivative of colistin must not be used - it is an
inactive pro-drug that breaks down slowly in
solution).11, 12 Agar dilution, disk diffusion, and
gradient diffusion are not currently recom-
mended by CLSI-EUCAST as these methods
yield unacceptably high error rates compared
to broth microdilution.11–13 We recommend
that the CLSI/EUCAST Joint Working Group
clinical breakpoints be used for colistin (Table 1).
Evidence Summary. CLSI14 and EUCAST15
established a Joint Working Group regarding
susceptibility testing and breakpoints for col-
istin.11, 12 Polymyxin B was not addressed by
this group. The CLSI/EUCAST Joint Working
Group recommended clinical breakpoints that
are harmonized for Acinetobacter sp and P. aerug-
inosa. These recommendations were approved by
the CLSI Antimicrobial Susceptibility Testing
Subcommittee in 2016.11,12 Breakpoints for
Enterobacteriaceae were also considered. How-
ever, there were insufficient data, and a clinical
breakpoint was not established. Rather, an epi-
demiological cutoff value (ECV) was defined,
based on the MIC distribution data for Klebsiella
aerogenes, Enterobacter cloacae, Escherichia coli,
K. pneumoniae, and Raoultella ornithinolytica. It is
important to note that CLSI recommended that
the ECV should be applied only to these species
because wild-type MIC distributions may be dif-
ferent for other genera and species of Enterobac-
teriaceae. Thus the clinical breakpoints for
colistin provided by the CLSI for P. aeruginosa
and Acinetobacter sp were a susceptible break-
point of 2 mg/L or lower and a resistant break-
point of 4 mg/L or higher.12 EUCAST
breakpoints for colistin for P. aeruginosa, Acineto-
bacter sp and Enterobacteriaceae are a susceptible
breakpoint of 2 mg/L or lower and a resistant
breakpoint of greater than 2 mg/L (Table 1).15
Future Research Needs. Research should be
directed toward defining reliable testing methods
for colistin that are more convenient than
microdilution techniques. Rapid diagnostics of
polymyxin resistance16–18 and defining Enter-
obacteriaceae MIC breakpoints are necessary.
Because polymyxin B breakpoints have not been
established, future research is necessary to evalu-
ate and define clinical breakpoints indepen-
dently for all species.
II. Is There a Recommended PK/PD Therapeutic
Target for Maximization of Efficacy for Colistin
and Polymyxin B?
Recommendations. R2: We recommend that for
colistin, an area under the plasma concentra-
tion-time curve across 24 hours at steady state
(AUCss,24 hr) of ~50 mghour/L is required that
equates to a target average steady-state plasma
concentration (Css,avg) of ~2 mg/L for total drug.
Although this target might be suboptimal for
lower respiratory tract infections, it is noted that
this should be considered as a maximum tolera-
ble exposure. Concentrations higher than this
were shown to increase both the incidence and
severity of AKI.
Table 1. CLSI/EUCAST Breakpoints for Colistin
Organism
Colistin MIC, mg/L
Susceptible Intermediate Resistant
CLSIa
Acinetobacter sp ≤ 2 – ≥ 4
Pseudomonas
aeruginosa
≤ 2 – ≥ 4
EUCAST
Acinetobacter sp ≤ 2 > 2
P. aeruginosa ≤ 2 > 2
Enterobacteriaceae ≤ 2 > 2
CLSI = Clinical and Laboratory Standards Institute;
EUCAST = European Committee on Antimicrobial Susceptibility
Testing; MIC = minimum inhibitory concentration.
a
For isolates of Enterobacter aerogenes, Enterobacter cloacae, Escheri-
chia coli, Klebsiella pneumoniae, and Raoultella ornithinolytica, CLSI
define insufficient clinical and pharmacokinetic/pharmacodynamic
(PK/PD) data to set a PK/PD-based breakpoint and cite epidemiolo-
gical cutoff values (ECVs) of 2 mg/L based on MIC distribution
data.11, 12
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R3: We recommend similar targets for poly-
myxin B as those listed for colistin. However,
we note that data are lacking for AUCss,24 hr
targets for polymyxin B. Emerging evidence sug-
gest a different toxicodynamic (TD) profile for
polymyxin B than colistin. Some evidence
indicates that an AUCss,24 hr target of 50–
100 mg hour/L, corresponding to a Css,avg of 2–
4 mg/L, may be acceptable from a toxicity
standpoint.
R4: We recommend that the exposures just
described for polymyxin B and colistin should
be considered the maximal tolerable exposures.
Although these recommended exposures should
achieve bacterial killing at the current MIC
breakpoints based on the mouse thigh infec-
tion model, both colistin and polymyxin B
when administered systemically (i.e., not
directly into the lungs) were shown in the
mouse lung infection model to be substantially
less effective.
Evidence Summary. The in vitro PD activity of
colistin and polymyxin B is virtually indistin-
guishable.19–21 Both polymyxins demonstrate
rapid bactericidal killing against susceptible
strains of P. aeruginosa,22, 23 A. baumannii,19, 20
and K. pneumoniae.24, 25 Concentrations above
the MIC result in extremely rapid initial killing,
with large decreases in colony-forming units
per milliliter (cfu/mL) occurring as early as
5 minutes following exposure.22 A modest postan-
tibiotic effect is evident for high concentrations
of colistin and polymyxin B.22 The PK/PD linked
parameter of the polymyxins was investigated in
in vitro PK models and animal models.
Clearly, for colistin, in vitro26, 27 and animal
studies28, 29 point to the free-drug area under
the concentration-time curve to MIC ratio
(fAUC:MIC) as the PK/PD index that is best cor-
related with efficacy. Fewer preclinical data are
available for polymyxin B.20, 21, 29, 30 However,
they also suggest that fAUC:MIC is the PK/PD
index that correlates best with antibacterial
activity. Because colistin and polymyxin B have
very similar molecular structures and in vitro
activity,1, 31 it is reasonable to conclude that
polymyxin B PK/PD indices and targets approach
those of colistin.
Studies have elucidated the fAUC:MIC target
for colistin in both in vitro systems and in ani-
mals. The most recent studies29 of systemically
administered colistin against A. baumannii and
P. aeruginosa in murine thigh and lung infection
models were used to determine fAUC:MIC
targets for various magnitudes of bacterial kill
and, as discussed earlier, to establish MIC break-
points. For colistin, the fAUC:MIC values to
obtain a 2 log10 reduction in bacterial count in
the experimental thigh infection model ranged
from 7.4–13.7 for P. aeruginosa and from 7.4–
17.6 for A. baumannii. The fAUC:MIC values to
obtain a 1 log10 reduction in bacterial count in
experimental thigh infection ranged from 6.6–
10.9 for P. aeruginosa and from 3.5–13.9 for
A. baumannii. Target fAUC:MIC values for 1 and
2 log10 kill in the lung infection model were
substantially higher. Indeed, for A. baumannii, it
was not even possible to achieve bacteriostasis
for two of the three tested strains with the
highest tolerable systemic dosage regimen of
colistin.29
Based on these data, a target plasma colistin
Css,avg of 2 mg/L was recommended for systemic
administration of CMS.6, 32, 33 This target is
based on the following considerations. First, it
accounts for the difference in the extent of pro-
tein binding between the plasma of mice and
critically ill patients.6, 32, 33 The protein binding
in human plasma is ~50%. Second, based on the
thigh infection model, this exposure would be
expected to achieve bactericidal activity against
an isolate with an MIC of 2 mg/L (the EUCAST
and CLSI breakpoint). It is important to note
that, unless the MIC of the infecting strain is
well below the breakpoint, this target is very
likely to be suboptimal for the systemic treat-
ment of a lung infection.29, 30 Third, it is con-
sidered unwise to target a higher plasma colistin
Css,avg because pharmacokinetic/toxicodynamic
(PK/TD) analyses in patients demonstrated that
concentrations greater than 2 mg/L are associ-
ated with an increase in both the incidence and
severity of AKI.34–36 Therefore, the proposed tar-
get concentrations of colistin should be consid-
ered the maximal tolerable target. Finally, even
though a plasma colistin Css,avg less than 2 mg/L
may be adequate for an isolate with a low MIC,
the susceptibility of the organism is often not
known at the initiation of therapy, and there-
fore, a target of 2 mg/L is appropriate when
starting CMS. Furthermore, given inaccuracies
with antibiotic susceptibility testing with the
polymyxins, relying on the reported MIC may
lead to suboptimal exposures.37
One group30 recently reported the results of
PK/PD studies for systemically administered
polymyxin B against K. pneumoniae in murine
thigh and lung infection models. The target val-
ues for 1 log10 reduction in bacterial count in
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the thigh model (fAUC:MIC 3.72–28.0) were
similar to those for colistin for the same magni-
tude of bacterial kill. Unlike colistin, 2 log10 kill
in the thigh model was not achieved even at the
highest tolerated dose of polymyxin B. Similar to
findings with colistin, polymyxin B was substan-
tially less effective against lung infections and
was not able to achieve stasis against any strain,
even at the highest tolerated systemic dose.
For polymyxin B, clinical PK/TD data are
scarce, and as described in detail later, it appears
to differ from CMS with regard to the risk of AKI
with currently used doses. In the absence of direct
quantitative data to establish an exposure–toxicity
relationship, clinicians should consider data
derived from a meta-analysis of 16 studies involv-
ing a total of 971 subjects who received intra-
venous (IV) polymyxin B.38 Pharmacokinetic
exposures in patients in these studies were simu-
lated based on patient characteristics and dosing
information given in each study and published PK
parameters for polymyxin B. The 25th, 50th and
75th percentiles of estimated polymyxin B AUCSS
were 46.7, 58.6, and 78.1 mg  hour/L, respec-
tively. Importantly, across all studies, 26.4% of
patients displayed a 50% or higher decrease in
creatinine clearance (Clcr). Based on these find-
ings, some experts suggest a target AUCss,24 hr as
high as 100 mg  hour/L for polymyxin B.39 However,
based on the recent lung infection model data for
systemically administered polymyxin B against
K. pneumoniae,30 these higher exposures may still
be insufficient to achieve killing in respiratory
tract infections. Thus the benefit (and true toxic-
ity risk) of these higher exposures remains
unclear. Therefore, the panel recommends the
same target exposures as for colistin (AUCSS of
~50 mghour/L).
It is important to note that the recommended
PK/PD exposure targets have been derived from
studies involving polymyxin monotherapy. Thus
the PK/PD targets should apply to polymyxin
monotherapy. Recent Hollow Fiber Infection
Model studies conducted in vitro using a high
bacterial density of organism and in the absence
of an immune system demonstrated a paradoxi-
cal effect for the polymyxins whereby higher
doses of polymyxin B and colistin further ampli-
fied high-level polymyxin resistance.20, 23, 40, 41
An inoculum effect was demonstrated for poly-
myxin monotherapy with bacterial killing activity
significantly attenuated at inocula consistent with
ventilator-associated pneumonia (VAP) or health
care–associated pneumonia (HAP).20, 23, 40, 41
Future Research Needs. Future research should
be directed toward defining optimal exposure
targets in critically ill patients to establish the
relationship between polymyxin exposure in
relation to clinical success and failure in this
patient population. The high proportion of
patients who fail polymyxin therapy, and other
patient-related factors, make the establishment
of PK/PD relationships in critically ill patients
extremely complex. PK/PD targets of polymyxins
should also be considered in the context of com-
bination therapy. The concentrations of
polymyxins necessary to potentiate other agents
would help determine whether safer exposures
can be given in combination regimens.
Polymyxin Pharmacokinetics
III. Should I Preferentially Use One Polymyxin
Over the Other?
Recommendations. R5: We recommend that clin-
icians have access to parenteral products of both
CMS and polymyxin B, so they can choose
between the two in particular circumstances.
R6: We recommend polymyxin B as the pre-
ferred agent for routine systemic use in invasive
infections. The rationale for this recommenda-
tion is that polymyxin B has superior PK charac-
teristics in humans as well as a decreased
potential to cause nephrotoxicity.
R7: We recommend colistin as the preferred
polymyxin for the treatment of lower urinary
tract infections given renal clearance of the pro-
drug CMS that then converts to the active moi-
ety colistin in the urinary tract.
Evidence Summary. There are several clinical
pharmacologic differences between CMS/colistin
and polymyxin B administered IV.42, 43 We point
the reader to an excellent review that highlights
the key differences between polymyxin B and col-
istin.42, 43 Polymyxin B appears to have superior
clinical PK characteristics for infections where it
is important to achieve rapidly and reliably and
then maintain a desired concentration in plasma.
In critically ill patients receiving IV CMS, plasma
concentrations of formed colistin rise slowly.
Even with a loading dose of CMS at the initiation
of therapy, it may take several hours to achieve
plasma colistin concentrations that may be effec-
tive. Polymyxin B is not administered as a pro-
drug, and therefore it is possible to use an IV
INTERNATIONAL CONSENSUS GUIDELINES FOR THE OPTIMAL USE OF THE POLYMYXINS 15
dose to achieve plasma concentrations more
rapidly that may be effective. In addition, dose
selection is more difficult for CMS because the
PK of CMS and formed colistin are subject to
substantially greater interpatient variability than
occurs with polymyxin B.42, 43 Moreover, in
patients with good renal function (Clcr greater
than 80 mL/minute), it is not possible to attain
reliably a plasma colistin Css,avg of 2 mg/L, a con-
centration regarded as a reasonable initial target
when MIC is unknown (see Section II),6, 32, 33
even with daily doses of CMS at the upper end
of approved doses (see Section VI).6, 32 The phar-
macokinetics of polymyxin B are not similarly
affected by renal function, and therefore it is pos-
sible to attain a plasma polymyxin B Css,avg of
2 mg/L reliably with approved daily doses, even
in patients with Clcr greater than 80 mL/minute
(see Section XI).44–47
The risk of AKI appears to be less with poly-
myxin B,48–54 although some of the comparative
studies are confounded by issues with different
experimental designs.8, 42, 43 Therapeutic drug
monitoring (TDM) is inherently more difficult
for colistin because of the need to ensure that
samples are collected in such a way as to mini-
mize ongoing in vitro conversion of CMS to col-
istin. However, CMS may be the preferred agent
for the IV treatment of urinary tract infections.
Urinary concentrations of colistin after adminis-
tration of CMS (mainly cleared by renal excre-
tion) can be high because of conversion of CMS
to colistin in the urinary tract.4, 43, 55, 56 In con-
trast, polymyxin B is predominantly cleared by
nonrenal mechanisms with a median urinary
recovery of 4.0% in patients.44
Future Research Needs. Although prospective
RCTs comparing parenteral polymyxin B and col-
istin in patients with various types of infections
are unlikely to be conducted, any comparative
observational data would further elucidate the
efficacy and toxicity differences between both
polymyxins. In particular, well-controlled safety
and efficacy studies comparing dose-optimized
colistin versus polymyxin B are of great interest.
Colistin Intravenous Dosing
IV. For CMS, What Is the Relationship Between
Different Dosing Units in the Literature?
Recommendation. R8: We recommend that hos-
pital guidelines and prescription orders specify
doses of CMS in either number of international
units (IU) or milligrams of colistin base activity
(CBA), corresponding to the labeling convention
used in the specific country. Because of the
international scope of these guidelines, doses in
the following sections are expressed in the
approximate equivalents of both of these con-
ventions. The conversion factor is 1 million IU
is equivalent to ~33 mg CBA.
Evidence Summary. Colistin is administered par-
enterally in the form of the inactive prodrug,
CMS. Unfortunately, two different conventions
are used in different parts of the world to label
vials of parenteral CMS and to express doses for
patients. Both conventions are based on microbi-
ological assessment. The parenteral products of
CMS available in Europe and some other parts
of the world are labeled in terms of IU. In con-
trast, parenteral CMS vials available in North
and South America and many other parts of the
world are labeled in terms of CBA, another way
of expressing microbiological activity.
As noted earlier, 1 million IU corresponds to
~33 mg CBA, and 1 million IU also corresponds
to ~80 mg of the chemical CMS.57 Thus it is
critical that doses must not be prescribed in
terms of milligrams of the chemical CMS.4
When reading the scientific literature, clinicians
must clearly understand whether doses reported
in milligrams refer to CBA or the chemical CMS.
Consistent global reporting of colistin doses is
critically important to promote safe and effective
use.58
Future Research Needs. International harmoniza-
tion is urgently needed to have a consistent
approach to specify all doses in either numbers
of IUs or milligrams of CBA.
V. Do I Need to Administer an Intravenous Load-
ing Dose When I Initiate Therapy with CMS?
Recommendation. R9: We recommend initiating
IV therapy with a CMS loading dose of 300 mg
CBA (~9 million IU) infused over 0.5–1 hours
and to administer the first maintenance dose
12–24 hours later.
Evidence Summary. After initiation of CMS ther-
apy in critically ill patients, plasma concentra-
tions of formed colistin were reported to
increase slowly over many hours or even
days,33, 59–61 although more rapid increases were
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also reported.62 Such variation in the rate of
concentration attainment of colistin is probably
related to brand-to-brand or batch-to-batch dif-
ferences in the complex chemical composition
(degree of methanesulfonation) of the CMS
administered to patients.63 The case for a load-
ing dose would be more compelling for a brand
or batch that undergoes slow conversion. Unfor-
tunately, there is no way of knowing (a priori)
the rate of in vivo conversion for a particular
batch. The impact of a loading dose on the risk
of developing AKI is unclear.52, 54, 64 Consider-
ing the need for timely antibiotic administration,
the therapeutic benefits of a loading dose may
justify the potential risk of AKI associated with
loading dose.65–67 The timing of the commence-
ment of the maintenance dose should be based
on the interval of the maintenance dose (e.g., if
the patient is placed on colistin every 12 hours,
the maintenance dose should start 12 hours
later).
Future Research Needs. More research is needed
to define the brand-to-brand and batch-to-batch
differences as they relate to degree of methane-
sulfonation and conversion to colistin. Addi-
tional data regarding the safety and efficacy of
loading doses are needed.
VI. What Should My Initial Daily Maintenance
Dose of CMS Be in Patients with Normal Renal
Function?
Recommendation. R10: We recommend that for
a patient with normal renal function, adminis-
ter a daily dose of 300–360 mg CBA (~9–
10.9 million IU), divided into two and infused
over 0.5–1 hour at 12-hour intervals. Monitor
renal function and adjust the daily dose
accordingly using the recommendations in
Table 2.
Evidence Summary. Determining initial daily
maintenance dose requires consideration of the
desired target average steady-state plasma con-
centration (Css,avg) of colistin. Based on transla-
tion of preclinical PK/PD data for P. aeruginosa
and A. baumannii in murine thigh infection mod-
els and the ECV for K. pneumoniae;11, 12, 14, 29, 68
clinical PK/TD data defining the relationship
between plasma colistin exposure and risk of
AKI in patients;34–36 and the fact that the MIC of
an isolate is often not known at initiation of ther-
apy, a target plasma colistin Css,avg of 2 mg/L was
suggested.6, 32 This target may be appropriate for
treatment of relatively accessible infections with
organisms having colistin MICs of 2 mg/L or
lower. However, it is important to recognize that
murine lung infections with P. aeruginosa and
A. baumannii were substantially more resilient to
systemic treatment than were murine thigh infec-
tions.29 Thus based on the preclinical data, a
plasma colistin Css,avg of 2 mg/L achieved via IV
administration may not be adequate for the treat-
ment of lung infections in critically ill patients,
especially those caused by organisms that have
elevated MIC organisms.6, 29
The daily doses of CMS to achieve a target
plasma colistin Css,avg of 2 mg/L (Table 2) were
proposed based on analysis of PK data from
more than 200 critically ill patients with a wide
range of renal function.6 For patients with a Clcr
greater than 90 mL/minute, a suggested maxi-
mum dose of 360 mg CBA (~10.9 million IU)
per day was proposed because of limited clinical
experience regarding the rate and impact of AKI
with daily doses above this level. Even with the
daily doses proposed for patients with Clcr
greater than 90 mL/minute (Table 2), only 30–
40% of patients are expected to achieve a plasma
colistin Css,avg of 2 mg/L or more,
6, 61 although
almost 80% of such patients may achieve a
Css,avg of 1 mg/L or greater.
6
Although weight-based dosing algorithms were
proposed as alternatives in the U.S. package insert,
Table 2. Look-up Table of Daily Doses of CMSa
Creatinine clearance, mL/
minuteb
Daily dose of CMS for
plasma colistin Css,avg of
2 mg/Lc
mg CBA/
day
Million IU/
day
0 130 3.95
5 to < 10 145 4.40
10 to < 20 160 4.85
20 to < 30 175 5.30
30 to < 40 195 5.90
40 to < 50 220 6.65
50 to < 60 245 7.40
60 to < 70 275 8.35
70 to < 80 300 9.00
80 to < 90 340 10.3
≥ 90 360 10.9
CBA = colistin base activity; CMS = colistin methanesulfonate; Css,
avg = average steady-state plasma concentration;
aTo achieve a desired target plasma colistin Css,avg of 2 mg/L for
patients with narrow windows of creatinine clearance. Reproduced
from reference 6 with minor modifications.
bAdjusted body weight should be used to estimate creatinine clear-
ance.
cDaily dose administered in two divided doses 12 hours apart.
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such as those in a current RCT of colistin, https://
clinicaltrials.gov/ct2/show/NCT01597973?term=
NCT01597973&rank=1.69 PK data do not sup-
port the need for weight-based dosing.
Future Research Needs. The dose suggestions in
Table 2 require validation by independent
studies. In particular, these recommended
doses need to be compared with lower histori-
cal dosing regimens to ensure the appropriate
balance between safety and efficacy is
achieved. Research is needed to define optimal
dosing strategies in patients with Clcr greater
than 80 mL/minute.
VII. Do I Need to Adjust the Daily Maintenance
Dose of CMS If the Patient Has Renal Impairment?
Recommendation. R11: We recommend that
CMS dose adjustments be made in patients with
renal insufficiency as provided in Table 2.
Evidence Summary. The apparent clearance of
colistin and hence the plasma colistin Css,avg
achieved from a given daily dose of CMS is influ-
enced by kidney function.6, 33, 62 Therefore, the
daily dose of CMS to target a plasma colistin Css,
avg of 2 mg/L should be adjusted for renal impair-
ment. Daily doses for patients with various
degrees of renal function are provided in Table 2.
The daily dose is divided into two doses, admin-
istered 12 hours apart, and each dose is infused
over 0.5–1 hour. If the daily dose is not reduced
in patients with decreased renal function, there is
an increased probability that the plasma colistin
Css,avg will be higher than 2 mg/L. This would be
expected to increase antibacterial activity but is
also expected to increase the likelihood of AKI.
Future Research Needs. Although it is critical to
adjust colistin doses in patients with renal
impairment, definitive knowledge of the subse-
quent concentrations obtained requires TDM.
Research is required to investigate the optimal
approach to implementing TDM including identi-
fication of the patient groups most likely to bene-
fit.
VIII. Does Renal Replacement Therapy Have Impli-
cations for Selection of Intravenous CMS Dosage
Regimens?
Recommendations. R12: We recommend that to
target a plasma colistin Css,avg of 2 mg/L in a
patient on intermittent hemodialysis (IHD), the fol-
lowing dosing schedule be utilized: On a nondial-
ysis day, administer a CMS dose of 130 mg CBA/
day (~3.95 million IU/day). On a dialysis day,
administer a supplemental dose of CMS 40 mg
CBA (~1.2 million IU) or 50 mg CBA (~1.6 mil-
lion IU) for a 3- or 4-hour IHD session, respec-
tively. If possible, the supplement to the baseline
(nondialysis) daily dose should be administered
with the next regular dose, after the dialysis ses-
sion has ended. Conduct IHD sessions as late as
possible within a CMS dosage interval to mini-
mize the amount of CMS and formed colistin lost
to the extracorporeal system.
R13: We recommend that to target a plasma
colistin Css,avg of 2 mg/L in patients prescribed
sustained low-efficiency dialysis (SLED) that 10%
of the CMS dose be added to the baseline daily
dose per 1 hour of SLED.
R14: We recommend that for patients pre-
scribed continuous renal replacement therapy
(CRRT), for a plasma colistin Css,avg of 2 mg/L,
to administer CBA 440 mg/day (~13.3 million
IU/day). This equates to 220 mg CBA every
12 hours (~6.65 million IU every 12 hours).
Evidence Summary. Colistin methanesulfonate
and formed colistin are efficiently cleared by
intermittent and continuous renal support
modalities; less information is available for SLED
than for shorter forms of IHD and
CRRT.6, 33, 70–77 Supplementary doses of CMS
are needed for patients receiving IHD or SLED.
IHD, SLED, and CRRT, each removes ~10% of
colistin an hour necessitating replacement of
10% of the daily dose per hour on these modali-
ties. Because the duration of CRRT (24 hrs) is
greater than the duration of SLED (often 8–
10 hrs), which is greater than the duration of
IHD (3–4 hrs), the supplementary doses needed
differ significantly as a function of dialysis type.
Apparent clearance of colistin and hence the
dose requirements of CMS are greater in patients
on CRRT than for patients with normal renal
function.6, 33, 76 Detailed dose suggestions for
patients receiving renal support have been pro-
posed.6, 75, 76
To target a plasma colistin Css,avg of 2 mg/L in
patients prescribed SLED, it is recommended
that 10% be added to the baseline daily dose per
1 hour of SLED. We provide the following prac-
tical example as an illustration.6
For a patient receiving a 10-hour nocturnal
SLED session each day and receiving CMS every
12 hours:
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• For a patient with Clcr of ~0 mL/minute, the
CMS dose would be the sum of the baseline
CMS dose (CBA dose of 130 mg/day
[~3.95 million IU/day], Table 2) plus a sup-
plementary dose comprising 10% of the
baseline dose per hour 9 10 hours.
• That is, for this patient, the CBA dose
would be 260 mg/day (~7.9 million
IU/day). In such a case, it may be most
convenient and safe to administer 130 mg
CBA every 12 hours (~3.95 million IU
every 12 hours).
Future Research Needs. Research is needed on
colistin dosing in SLED patients, particularly
with regard to the impact of different dialysis
membranes on colistin removal. The preceding
recommendations for SLED were based on small
sample sizes with the use of medium- to high-
flux filters. Removal would be expected to be
decreased with lower flux filters.
Polymyxin B Intravenous Dosing
IX. Do I Need to Administer an Intravenous Load-
ing Dose When I Initiate Therapy with Polymyxin
B?
Recommendation. R15: We recommend a load-
ing dose of 2.0–2.5 mg/kg for polymyxin B,
based on total body weight (TBW) (equivalent
to 20,000–25,000 IU/kg) over 1 hour.
Evidence Summary. A population PK study in
critically ill patients showed that with a regimen
of 1.25 mg/kg (equivalent to 12,500 IU/kg)
every 12 hours, plasma polymyxin B concentra-
tions achieved after the first dose were ~56–70%
of the concentrations observed at steady state.44
Using Monte Carlo simulations, it was estimated
that with a loading dose of 2.0 mg/kg (equiva-
lent to 20,000 IU/kg), day 1 exposures would
likely be 76–94% of exposures at steady state.44
There is a paucity of data regarding the clinical
safety and efficacy of a polymyxin B loading
dose strategy. However, one analysis found no
association between loading dose of either poly-
myxin B or colistin and nephrotoxicity (adjusted
hazard ratio [aHR] 0.78, 95% confidence inter-
val [CI] 0.42–1.46).54 In this analysis, 36
patients received an average polymyxin B load-
ing dose of 1.9  0.5 mg/kg.54 Conversely,
although not statistically significant, loading
doses were more frequently administered in
patients who presented with neurotoxicity com-
pared with patients who did not present with
this adverse event (2 of 6 [33.3%] and 7 of 68
[10.3%], respectively; p=0.15).78
Although it is reasonable to administer load-
ing doses to all patients, priority should be
given to those who are critically ill such as
those with sepsis or septic shock. Pharmacoki-
netic data do not support capping upper abso-
lute dose (i.e., expressed in milligrams) in
obese patients. However, experience with the
administration of more than 200 mg per infu-
sion is limited,78, 79 and infusion-related
adverse effects, which include sudden thoracic
pain, paresthesias, dizziness, dyspnea, and
hypoxemia, were reported at a crude incidence
of 0.9% (95% CI 0.2–3.2) and may increase
with such doses.78
Future Research Needs. Additional research is
needed to define the safety and efficacy of high
initial dose polymyxin B regimens. Although
administration of doses higher than 3 mg/kg
(equivalent to 30,000 IU/kg) were reported in
patients,44, 78 more data are needed on the
safety as well as the clinical and microbiological
impact of these regimens.
X. What Is the Recommended Initial Daily Mainte-
nance Dose for Polymyxin B in Patients with Nor-
mal Renal Function?
Recommendation. R16: We recommend that for
patients with severe infections, a polymyxin B
dose of 1.25–1.5 mg/kg (equivalent to 12,500–
15,000 IU/kg TBW) every 12 hours is infused
over 1 hour.
Evidence Summary. As discussed earlier, consid-
ering that fAUC:MIC targets for 1 log10 kill for
polymyxin B against K. pneumoniae30 showed
generally good agreement with the correspond-
ing values for colistin against P. aeruginosa and
A. baumannii in the murine thigh infection
model,29 and given the similar plasma unbound
fractions (i.e., ~0.50) of polymyxin B44 and col-
istin6 in humans, a Css,avg of 2 mg/L seems to be
an appropriate target for polymyxin B dosing
guidance. This target may be revised as more
information becomes available from preclinical
studies to inform PK/PD relationships against
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gram-negative pathogens and from clinical stud-
ies to inform the PK/TD relationship for nephro-
toxicity.
With doses of 2.5 and 3.0 mg/kg/day (equiva-
lent to 25,000 and 30,000 IU/kg/day, respec-
tively), 90% of patients, as determined by Monte
Carlo simulations, would be expected to achieve
an AUC of polymyxin B at steady state of at
least 44.3 and 53.1 mg hour/L, respectively,44
that corresponds to Css,avg of 1.8 and 2.2 mg/L,
respectively. Thus against isolates with poly-
myxin B MICs of 2 mg/L, the PK/PD target for 1
log10 kill of P. aeruginosa, A. baumannii, and
K. pneumoniae in murine thigh infection29, 30
will have an estimated probability of target
attainment of more than 90% with either dosing
strategy. Given the concerns mentioned earlier
with antibacterial activity of systemically admin-
istered polymyxins in lung infections,29, 30
higher plasma concentration targets might be
necessary to achieve adequate antimicrobial
activity in different infection sites. However, due
to the lack of clinical safety data, a maintenance
dose higher than 3 mg/kg/day (equivalent to
30,000 IU/kg/day) cannot be recommended at
this time. A target of 2 mg/L is recommended
even for isolates with an MIC lower than 2 mg/L
in patients with severe infections.80 Unfortu-
nately, in the routine clinical microbiology labo-
ratory setting, the MIC cannot be determined
with enough accuracy at this stage, and a target
of 2 mg/L therefore seems to be prudent in all
cases.
Pharmacokinetic data do not support capping
upper absolute doses (i.e., expressed in mil-
ligrams) in patients with high TBW. However,
experience with infusions of more than 200 mg
remains limited,78, 79 and infusion-related
adverse effects may increase with such doses.
No specific recommendation is available in
the package insert concerning the duration of
infusion. However, in recent PK analyses reflect-
ing real-world use of polymyxin B, doses were
safely administered over 1–4 hours in most
patients.44–46, 81 Because there might be a poten-
tial benefit on renal toxicity of higher peak-to-
trough differences,82 infusions over 1 hour
might be preferred over longer infusions if well
tolerated by patients.
Future Research Needs. Additional research is
needed to define the safety and efficacy associ-
ated with optimal maintenance dosing of poly-
myxin B.
XI. Do I Need to Adjust the Daily Polymyxin B
Maintenance Dose If the Patient Has Renal Impair-
ment?
Recommendation. R17: We recommend that daily
maintenance doses of polymyxin B should not be
adjusted if the patient has renal impairment.
Evidence Summary. Polymyxin B is not signifi-
cantly eliminated by the kidneys, and clinical
PK studies demonstrate that polymyxin B clear-
ance does not depend on Clcr.
44–47 Therefore,
no PK rationale exists for adjusting doses
according to renal function. Lowering doses in
patients with decreased Clcr will lead to lower
polymyxin B plasma concentrations. The pack-
age insert for polymyxin B recommends dose
reducing “downward for individuals with kidney
impairment”; however, it is unclear what data
spurred this recommendation.83 More recent PK
data as well as enhanced understanding of renal
handling of polymyxin B refute this recommen-
dation. If unnecessary renal dose adjustments
are made in patients, there is potential for drug
underexposure and clinical failure. Clinical liter-
ature supports this claim because doses of
1.2 mg/kg/day or less (equivalent to 12,000 IU/
kg/day or less), which were commonly pre-
scribed to patients with renal insufficiency, were
associated with increased mortality in patients
receiving polymyxin B.80
Future Research Needs. Package insert dose
adjustment for renal impairment should be
revised because it is not supported by modern
PK data. Furthermore, larger PK studies in
patients with renal insufficiency are needed to
validate the recommendations provided here.
XII. Does Renal Replacement Therapy Have Impli-
cations for Selection of Intravenous Polymyxin B
Dosage Regimens?
Recommendation. R18: We recommend that nei-
ther the loading dose nor maintenance dose be
adjusted in patients receiving renal replacement
therapy.
Evidence Summary. There are only two reports
of the PK of polymyxin B in patients receiving
renal replacement, and both involved CRRT. The
first report involved two patients receiving con-
tinuous venovenous hemodialysis (CVVHD),79
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and the second described one patient receiving con-
tinuous venovenous hemofiltration (CVVHF).84 In
the former two patients, the CVVHD was
responsible for 5.6% and 12.2% of polymyxin B
total body clearance.79 In the latter patient, the
polymyxin B extraction across the extracorporeal
cartridge was only 5.0%.84 This degree of elimi-
nation is similar to the extent of renal elimina-
tion in critically ill patients not receiving
extracorporeal modalities (median 4%, range
1.0–17.4%).44 Although data are limited to these
three cases, they suggest that CVVHD and
CVVHF are unlikely to remove more than ~12%
of total body polymyxin B, similar to the per-
centage recovered in the urine in patients not
requiring renal replacement therapy.44 Thus on
the basis of these PK data, dose modifications
are not warranted in patients receiving these
forms of CRRT.
Clinical data also suggest that dose reductions
in patients on CVVHD can potentially lead to
underexposure and increased risk of poor out-
comes.85 Higher total daily doses were associ-
ated with lower 30-day mortality in bivariate
analysis (p=0.04), and a total daily dose of
200 mg or more (equivalent to 2 million IU or
more) was associated with a lower risk of 30-
day mortality in multivariate analysis (p=0.02).85
Thus dose reductions for patients receiving renal
replacement therapy are not only unwarranted
based on the limited amount of PK data, but the
clinical evidence suggests they might potentially
be harmful to patients.
Currently no PK data are available on poly-
myxin B in patients receiving intermittent renal
replacement therapy.
Future Research Needs. PK data are lacking for
polymyxin B in patients receiving IHD and
SLED, and only minimal data are available for
CRRT. Larger PK analyses are urgently needed
to further refine dosing recommendations.
XIII. Is There a Role for Therapeutic Drug Moni-
toring of Colistin or Polymyxin B?
Recommendation. R19: We recommend that
TDM and adaptive feedback control (AFC) be
used wherever possible for both colistin and
polymyxin B.
Evidence Summary. The polymyxins display
characteristics that suggest TDM and AFC would
be beneficial. Drug dose cannot be safely
optimized using clinical observation and dosing
algorithms alone, especially in the early treat-
ment period that is a critical determinant of
prognosis. Moreover, if therapy is unsuccessful,
potential dire consequences may ensue (clinical
ones for the patient concerned in addition to
emergence of polymyxin resistance). In addition,
based on the more abundant data for colistin,
there are established relationships between
plasma exposure and both antibacterial effect29
and risk of AKI.34–36 The therapeutic window is
extremely narrow because plasma exposures
required for antibacterial effect overlap those
associated with increased AKI risk.6 And the
substantial interpatient variability in PK cannot
be accounted for by known patient factors (such
variability is substantially greater for IV colistin
than polymyxin B).6, 44, 61
The use of TDM as an aid to dosing CMS was
reported for a small number of patients,86, 87
but the benefit was not demonstrated in appro-
priately designed studies.4 For colistin, it is
essential to ensure that sample collection, han-
dling, and analysis are conducted appropriately
to minimize ex vivo conversion of CMS to col-
istin.33, 59 For colistin, by collecting blood sam-
ples just before the next dose (when CMS
concentrations are the lowest), the potential for
measurement of artificially elevated plasma col-
istin concentrations is minimized but not elimi-
nated. For polymyxin B sample collection,
handling and analysis for TDM are substantially
less complicated because this polymyxin is
administered directly, not as an inactive pro-
drug. As stated earlier, using TDM, the target
concentration is 2 mg/L for susceptible microor-
ganisms, irrespective of the MIC provided by the
routine clinical microbiology laboratory.
Future Research Needs. Real-time PK/PD/TD
profiles obtained from patients during poly-
myxin therapy are needed so that maximally
precise, patient-specific PK information can be
obtained. Such data would inform evolving
dose optimization at the individual patient
level.
XIV. What Strategies Can Be Used to Decrease the
Incidence of Acute Kidney Injury in Patients
Receiving Colistin or Polymyxin B Therapy?
Recommendation. R20: We recommend, wher-
ever possible, that concomitant nephrotoxic
agents should be avoided in patients receiving
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colistin or polymyxin B (Strong recommendation,
moderate quality evidence).
Remark: This recommendation was initially
graded with low confidence because data were
observational. However, the evidence quality
was upgraded due to the consistent large magni-
tude of the effect of administration of concomi-
tant nephrotoxins on the incidence of AKI with
no important threats to the validity of the data.
Evidence Summary. Undoubtedly, nephrotoxicity
is the most clinically relevant and dose-limiting
adverse reaction of the polymyxins. The inci-
dence of nephrotoxicity varies widely in the lit-
erature from 0% to more than 60% largely due
to heterogeneous patient populations, differing
definitions of nephrotoxicity, wide ranges of
polymyxin doses administered, and differences
in both severity of illness and the presence/ab-
sence of various other risk factors for the
patients being studied.34, 36, 50, 54, 88–91 Con-
temporary studies, using commonly accepted
polymyxin doses and AKI definitions, place the
rate of associated nephrotoxicity in the 20–50%
range for both polymyxins.34, 36, 50, 54, 88–91
Risk factors vary between studies, but a few
common factors are identified throughout the
literature. More advanced age was identified as a
risk factor in multiple analyses, although the so-
called cutoff age for increased risk is inconsis-
tent. Weight, irrespective of dose given, was
shown to be a risk factor for nephrotoxicity for
both colistin88 and polymyxin B.92 Chronic
comorbid conditions and the presence of hypoal-
buminemia were reported as risk factors for
nephrotoxicity.88, 92 Although these factors can
help clinicians identify those patients at highest
risk of AKI while receiving polymyxin therapy,
they are not modifiable. Clinicians should work
to address modifiable risk factors for AKI, and
the recommendations represent the panel’s view
regarding how best to accomplish this.
Receipt of concomitant nephrotoxic agents is
a consistent risk factor for AKI in patients
receiving polymyxin therapy. Although many
nephrotoxins have been identified as potential
risk factors, only a few would be considered
modifiable. For example, receipt of calcineurin
inhibitors, acute administration of loop diuretics,
and vasopressors have all been associated with
polymyxin-associated nephrotoxicity; however,
these exposures often cannot be avoided. Con-
versely, the use of IV contrast media for diag-
nostic testing, administering nonsteroidal
antiinflammatory drug or angiotensin-converting
enzyme inhibitor therapy, and/or receipt of other
nephrotoxic antibiotics, most notably van-
comycin, should be assessed by clinicians and
avoided when possible.93, 94 Although combina-
tion therapy with colistin and vancomycin
showed both in vitro synergy95 and select clini-
cal data suggest a potential clinical benefit of
this combination,93, 94 multiple analyses with
both colistin94, 96 and polymyxin B89 showed
concomitant vancomycin to be an independent
predictor of polymyxin-associated AKI; thus this
combination should be avoided. In addition,
analyses demonstrated rifampin90 coadministra-
tion to increase the risk of nephrotoxicity. Fur-
thermore, concomitant aminoglycosides were
also identified as independent predictors of col-
istin-associated AKI.91 Given the emergence and
spread of XDR gram-negative bacteria, including
carbapenem-resistant Enterobacteriaceae (CRE),
we acknowledge that aminoglycosides frequently
are often one of the few agents to which these
organisms are susceptible, and combination ther-
apy involving aminoglycosides and polymyxins
might be an attractive alternative and in some
cases might be unavoidable.
Future Research Needs. Data demonstrating the
impact of purposeful avoidance of the nephrotoxic
agents described earlier on prevention of AKI are
lacking. Such data would enhance the quality of
the evidence supporting this recommendation.
Future research is needed to evaluate the safety
and efficacy of polymyxin + aminoglycoside ther-
apy. Timely monitoring of renal function is a criti-
cal aspect of detecting AKI for the polymyxins. As
such, further research on biomarkers that respond
rapidly to renal insult would be highly beneficial
for toxicodynamic optimization.
Recommendation. R21: We recommend that
doses greater than those listed in this guideline
for colistin or polymyxin B be avoided in the
absence of TDM (Best practice recommendation).
Remark: This recommendation was not
assessed using GRADE. There is an absence of
data testing this strategy. Higher doses have the-
oretical advantages, but the comparative safety
and efficacy of those are unavailable based on
the currently available literature. This recom-
mendation prioritizes safety, due to the absence
of efficacy data with higher dosing strategies.
Furthermore, although dose increase or decrease
based on serum concentrations is rational from a
PK, PD, and TD standpoint, data are lacking to
assess the safety and efficacy of such a strategy.
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Evidence Summary. The most important risk
factor for polymyxin-associated AKI is the mag-
nitude of polymyxin exposure. Higher CMS
doses are consistently identified as a risk factor,
with CBA doses higher than 5 mg/kg/day (equiv-
alent to ~152,000 IU/kg/day) consistently posing
the highest risk. Similarly, associations were
seen with absolute polymyxin B doses of 150,
200,97 and 25080 mg/day or higher. Not surpris-
ingly, colistin serum steady-state concentrations
were also associated with AKI. Average steady-
state concentrations of 1.9–2.3 mg/L were asso-
ciated with higher degrees of toxicity than lower
concentrations,35 whereas day 3 trough concen-
trations of 3.33 and 2.42 mg/L or higher were
associated with AKI at days 7 and 14, respec-
tively.34 Importantly, in the latter study, of the
26 patients who had colistin trough values
higher than 2.2 mg/L on day 3, 17 (65%) and
22 (85%) had toxicity at days 7 and 14, respec-
tively.34 These PK/TD studies serve as the basis
of the maximal tolerable dose described in earlier
recommendations in these guidelines, and we
would recommend against giving higher expo-
sures.
Future Research Needs. Studies are needed that
weigh the risk-to-benefit ratio of clinical cure of
infection with the development of nephrotoxic-
ity. Furthermore, investigation regarding dosing
regimens (i.e., once/day, multiple times/day, or
continuous infusions) or other novel dosing
strategies and their impact on nephrotoxicity
should also be undertaken.
Recommendation. R22: In countries where both
agents are available, we recommend preferential
use of polymyxin B to limit the rate of poly-
myxin-associated AKI (Weak recommendation,
low-quality evidence).
Remark: This recommendation started with
low-quality evidence given the observational
data used to make the recommendation. The
confidence for the recommendation could not be
significantly upgraded or downgraded based on
the evidence. The relative consistency of the
findings of the published literature and rate of
AKI between the two polymyxins were consider-
ations for upgrading the strength of the quality
of the evidence. However, these were counter-
balanced by some of the data that did not
show a safety advantage with polymyxin B. In
addition, comparative studies are also con-
founded by the different doses of colistin and
polymyxin B used in comparing AKI. A strong
recommendation cannot be made until ade-
quately powered prospective dose-optimized
studies are performed.
Evidence Summary. When polymyxins reemerged
in the 1980s, one of the main drivers of prefer-
ential use of CMS over polymyxin B was the his-
torical belief, driven by anecdotes rather than
evidence, that colistin was the safer option with
respect to nephrotoxicity. Modern-day data have
debunked this belief, and interestingly there is a
suggestion that polymyxin B might in fact be
safer, with respect to the kidneys, than colistin.
Data from kidney cell lines98 as well as ani-
mals99 suggest that polymyxin B and colistin,
as would be expected from their similar chemi-
cal structures, have similar toxic effects on the
kidney.
However, in the six currently available clinical
studies assessing comparative nephrotoxicity rates
between the polymyxins, five displayed at least
some suggestion of increased and/or more severe
nephrotoxicity with colistin.48, 49, 52, 54, 98, 100
The one outlier to this trend was limited by small
numbers (only 30 and 39 patients receiving poly-
myxin B and CMS were evaluable for AKI,
respectively).48, 49, 50, 51, 52, 54 A systemic review
and meta-analysis53 summarizes the published
studies. Taken together, these data suggest that
polymyxin B is associated with less AKI in
patients.
Regardless of the mechanism, the current data,
although limited in quality, suggest that poly-
myxin B is less likely to cause nephrotoxicity than
CMS. Until further evidence becomes available,
clinicians should consider polymyxin B as the
preferred alternative to decrease the risk of poly-
myxin-associated AKI. An exception to this would
be for the treatment of urinary tract infections,
where CMS/colistin may be the preferred agent.
Future Research Needs. The main areas for pri-
oritization of future research include prospective
comparative trials assessing AKI rates with dose-
optimized polymyxins, investigation into the
mechanisms of potential discordant toxicity rates
between the agents, and finally whether dose-
optimized polymyxins differ in their rates of
nonnephrotoxic adverse reactions, most notably
neurotoxicity. In addition, studies comparing
neurotoxicities and skin hyperpigmentation
(e.g., skin darkness of face, ears, neck, and
upper chest and head during therapy101) for
polymyxin B versus colistin require future
studies.
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Recommendation. R23: Until further data
become available, we do not recommend the
routine use of antioxidants for the primary pur-
pose of reducing polymyxin-associated nephro-
toxicity (Weak recommendation, very low-quality
evidence).
Remark: The quality of the evidence was ini-
tially low given that both underpowered ran-
domized controlled and observational data were
used for the assessment. The data suffered from
every potential reason for downgrading the data
(risk of bias, inconsistency, indirectness, impre-
cision, and publication bias) and therefore were
rated as very low-quality evidence. The recom-
mendation was weak, given that animal data
support a potential protective effect as well as
the general lack of risk of patient harm with the
administration of antioxidants.
Evidence Summary. Interest in using antioxi-
dants, most notably ascorbic acid, has been
increasing as a nephroprotective mechanism in
patients receiving polymyxin therapy. This stems
from preclinical observations that in polymyxin-
induced nephrotoxicity, oxidative stress from
reactive oxygen species initiates renal cell apop-
tosis. Animal models supported this protective
role of ascorbic acid by demonstrating that
administration can decrease kidney tissue apop-
tosis and subsequent tubular damage.102
Clinical data exploring the impact of ascorbic
acid on limiting nephrotoxicity are scarce and
have displayed conflicting results. One group103
assessed nephrotoxicity rates with a novel dos-
ing regimen based on recent PK advances.
Interestingly, although not the primary intent
of the analysis, both bivariate (30% vs 67%;
p<0.05) and multivariate analyses (adjusted
odds ratio [aOR] 0.27, 95% CI 0.13–0.57) sug-
gested that concomitant administration of ascor-
bic acid was protective against nephrotoxicity.
Conversely, a small RCT in 28 patients failed
to show any benefit of 4 g/day of ascorbic acid
on the rates of colistin-associated nephrotoxic-
ity.104 Therefore, although a promising therapy,
the current data are insufficient to warrant a
recommendation in favor of routine adminis-
tration of ascorbic acid or any other antioxi-
dant for the prevention of polymyxin-associated
AKI.
Future Research Needs. Adequately powered and
sufficiently controlled prospective studies are
warranted to assess the impact of ascorbic acid
or other antioxidants on the incidence and/or
severity of polymyxin-associated nephrotoxicity.
XV. If My Patient Develops AKI While on Colistin
or Polymyxin B, Should I Decrease the Dose?
Recommendations. R24: We recommend that if a
patient develops AKI while on colistin, the daily
dose should be decreased to the appropriate ren-
ally adjusted dose for a plasma colistin Css,avg of
2 mg/L (Table 2).
R25: We recommend that doses should not be
decreased, outside of the renal dosing recom-
mendations for colistin, particularly in patients
who develop AKI when colistin or polymyxin B
is being administered for a life-threatening infec-
tion, a deep-seated infection, or when the infect-
ing pathogen has an MIC higher than 1 mg/L
(Strong recommendation, low-quality evidence). If
the MIC of the infecting pathogen and/or the
nature of the infection suggest that targeting a
lower plasma concentration may be adequate,
consideration should be given to decreasing the
dose to target a different Css,avg of colistin (Best
practice recommendation).
R26: We recommend that cessation of therapy
may be considered in patients who develop AKI
if infection diagnosis is uncertain or when an
alternative less nephrotoxic drug is available
(Best practice recommendation).
Evidence Summary. Although clinical PK data
support the need for dose adjustment in AKI for
colistin, they do not for polymyxin B.6, 44, 45 It
is a reasonable hypothesis that patients who
develop AKI have “supratherapeutic” polymyxin
plasma concentrations, but evidence from col-
istin studies suggests considerable overlap
between the “therapeutic” and “nephrotoxic”
plasma concentrations of polymyxins among
patients who develop AKI.34–36 It is also impor-
tant to note that AKI may be precipitated by
sepsis arising from inadequate treatment of
infection.105
The rationale for the recommendation not to
lower doses of polymyxin B in the setting of a
decline in renal function is that lowering doses
in these patients will ultimately lower serum
concentrations of polymyxin B, and although
that might limit toxicity, there is a greater con-
cern that it would compromise therapeutic effi-
cacy as was demonstrated in published studies.
For polymyxin B, data suggested that higher
doses, even in the setting of AKI, improve
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outcomes. One retrospective study with 276
patients showed a lower risk of in-hospital
mortality (aOR 0.43, 95% CI 0.23–0.79,
p=0.007) in patients receiving high-dose poly-
myxin B (200 mg/day or more) despite the
development of moderate or severe renal
injury, defined as 100% or more increase in
serum creatinine from baseline or need for
hemodialysis.97 In a larger multicenter prospec-
tive cohort with 410 patients, a polymyxin B
dose of 150 mg/day or higher was associated
with a nonsignificant protective effect on 30-
day mortality (aHR 0.74, 95% CI 0.51–1.07,
p=0.11) in patients who developed AKI accord-
ing to the RIFLE criteria.92
In patients who have less severe infections,
are clinically stable, and are receiving combina-
tion therapy, or those with infecting organisms
with MICs of 1 mg/L or lower, it is reasonable
to reduce the dose in the setting of AKI. For
such patients receiving colistin, a lower steady-
state plasma concentration may be targeted by
making proportional adjustment to the daily
doses in Table 2 or by using the reported dosing
algorithm.6 Because the process regarding how
exactly to achieve this and evidence to support
this strategy is lacking, we find it reasonable to
modify the dose to target a steady-state concen-
tration of 1.5 mg/L in certain clinical scenarios.
A similar strategy can be used for polymyxin B.
For polymyxin B, in similar clinical scenarios
as described earlier for colistin, it would be rea-
sonable to decrease the dose to the lower end of
the package insert range. The evidence to sup-
port this strategy for polymyxin B and colistin is
currently lacking, but it is considered appropri-
ate in these settings because the likelihood of
achieving only subtherapeutic drug exposure is
significantly diminished, and continued declines
in renal function might adversely impact clinical
outcomes. Similarly, clinical judgment should be
used to decide whether or not to continue poly-
myxin therapy in patients who develop AKI and
have an unconfirmed microbiological infectious
etiology. The potential benefit of maintaining
treatment should be weighed against the risk of
worsening AKI on a case-by-case basis.
Future Research Needs. Although research is
emerging regarding the association between
exposure of colistin and polymyxin B and toxic-
ity, the precise PK/TD profile has yet to be fully
elucidated as it relates to the time frame and
onset of nephrotoxicity. Therefore, future
research needs to further elucidate these targets.
Data pertaining to clear dose modifications in
the setting of AKI and the impact it has on the
progression and/or resolution of AKI and clinical
efficacy are also urgently needed.
Polymyxin Combinations
Polymyxin combination therapy is a heavily
debated and controversial topic. For multiple
reasons, combination therapy might be advanta-
geous. First, it is now very clear that plasma
concentrations of colistin are suboptimal in a
substantial proportion of patients, even when
daily doses of CMS are at the upper limit of the
approved product label.6, 33, 59–61 Similarly,
plasma polymyxin B concentrations achieved
among patients receiving the current upper limit
daily dose are not likely to be reliably efficacious
in many clinical scenarios including respiratory
tract infections.44 Second, it is not possible to
simply increase the daily doses of CMS or poly-
myxin B beyond doses recommended in this
document due to the potential for nephrotoxic-
ity that is the major dose-limiting adverse
effect.8, 52, 90 Third, the emerging body of evi-
dence in preclinical lung infection models sug-
gests poor in vivo response to the polymyxins
when administered parenterally.29, 30 Finally,
polymyxin resistance is increasing worldwide
with several recent reports of clinical failure
and resistance emergence during monother-
apy.106–109 With the recent report of mobile
colistin resistance genes,16–18, 110, 111 the pres-
ence of heteroresistance,19 and the association
between colistin resistance and increased risk of
in-hospital mortality,106 there is mounting support
for strategies to optimize polymyxins therapeuti-
cally including combination therapy.41, 111–113
There is a mechanism-based rationale for using
polymyxins in combination with other antimi-
crobials that display synergy with a membrane
permeabilizer (such as the polymyxins) allow-
ing for increased concentrations of companion
antibacterial agents that have intracellular
targets.109, 114–116
Unfortunately, the clinical literature on com-
bination therapy versus monotherapy is difficult
to interpret due to limitations in many stud-
ies.117, 118 The first type of limitation relates to
the characteristics of the critically ill patient
population that develop infections due to car-
bapenem-resistant gram-negative bacilli. These
are generally complex patients, with preexisting
comorbidities who experience extremely high
rates of treatment failure and death irrespective
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of infection-related outcome. Because the pri-
mary outcome in many analyses is all-cause
mortality, defining the effectiveness of combina-
tion versus monotherapy based on this outcome
is extremely challenging. In addition, patients
requiring polymyxin therapy frequently have sig-
nificant delays in time to appropriate therapy
that may limit the clinical impact of treatment
strategies. Furthermore, finding data comparing
monotherapy and combination therapy where
concomitant antibiotic exposure is minimized is
unrealistic because critically ill patients fre-
quently are treated empirically for concomitant
infections with a plethora of various different
antimicrobials. Some of these antibiotics, such as
vancomycin, that lack individual activity against
gram-negative bacteria have displayed synergy
with the polymyxins in vitro due to cell wall
and membrane perturbations.94 This leads to a
potential scenario where patients in a so-called
monotherapy group might not truly have
received a monotherapeutic regimen. Another
characteristic that makes these analyses difficult
to interpret is that different types of car-
bapenem-resistant organisms are often grouped
together. The assumption is that all carbapenem-
resistant organisms classified dichotomously
according to MIC breakpoints are identical and
will respond identically to therapy, regardless of
mechanism of resistance and specific MIC value,
but it is unlikely that this is the case.
Furthermore, although more recent analyses
have begun to examine dose-optimized poly-
myxin therapy, most publications to date do not
describe the dosing of polymyxins or other com-
bination agents, use suboptimal polymyxin
doses, and/or do not clearly report renal dosing
adjustments or MIC values of the polymyxins
and/or other antimicrobials used in combination
regimens for the pathogens. This is further com-
plicated by the fact that the vast majority of pre-
vious combination studies used colistin, rather
than polymyxin B, the latter of which has a
more favorable and predictable PK profile. Most
analyses are retrospective observational studies
that have inherent biases (such as confounding
by indication), making it difficult to interpret
the results clearly.117
Finally, it is very important to consider site of
infection in studies. Whereas most of the clinical
studies with CRE evaluated bloodstream
infection (BSI), most of the studies for carbapenem-
resistant A. baumannii (CRAB) and carbapenem-
resistant P. aeruginosa (CRPA) evaluated pneumonia.
Polymyxins administered parenterally were
shown to be far less effective in murine lung
infection models than in thigh infection mod-
els.29, 30 Therefore, although the clinical data,
presented below, attempt to provide evidence
toward the selection of polymyxin monotherapy
versus polymyxin combination therapy, the
inclusion of a variety of sites of infection within
a given trial makes interpretation challenging
because different pharmacologic considerations
exist in the treatment of different infection sites.
In this section, we describe the latest of pub-
lished evidence from clinical studies on poly-
myxin monotherapy versus combination therapy
for the three major target organisms: CRE,
CRAB, and CRPA. We assess the evidence
regarding combination therapy in two different
types of scenarios. The first is when the poly-
myxin is combined with an agent to which the
infecting pathogen is susceptible (R27, R29, and
R31). The second is when the polymyxin is
combined with an agent to which the pathogen
lacks in vitro susceptibility (i.e., a “nonsuscepti-
ble” agent) (R28, R30, and R32). We acknowl-
edge the rigorous debate by noting the
controversies surrounding polymyxin combina-
tion versus monotherapy, often in the absence of
RCTs.
Given the controversies regarding monother-
apy versus combination therapy for polymyxins,
it is important to note the panel did not
achieve unanimity on this topic, due to a vari-
ety of factors including limitations of published
studies, lack of clear clinical evidence, and
weighing the potential benefit-to-risk ratio of
combination versus monotherapy. Therefore, a
decision was made for authors to vote on the
recommendations R27 to R32. Some authors
abstained from the vote. Based on these voting
results, these guidelines provide the panel’s
consensus recommendations. In some cases, we
labeled recommendations as “best practice rec-
ommendations,” particularly in scenarios where
the recommendations are in contrast to the cur-
rently published data and/or lack sufficient
RCT evidence and represent the views of most
panel members as opposed to quality published
studies.
The recommendations voted on and thus serv-
ing as guideline recommendations R27 to R32
are not meant to serve as guideline recommenda-
tions for the optimal treatment of carbapenem-
resistant organisms and are not recommending
preferential use of polymyxin-based therapy for
these organisms. Rather, the recommendations
address scenarios where a clinician has already
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decided to use polymyxin-based therapy and is
trying to decide between monotherapy and com-
bination therapy.
XVI. Should Monotherapy or Combination Therapy
for Polymyxin B or Colistin Be Used to Treat
Patients with CRE Infections?
Recommendations. R27: We recommend that for
invasive infections due to CRE, polymyxin B or
colistin be used in combination with one or
more additional agents to which the pathogen
displays a susceptible MIC (Strong recommenda-
tion, very low-quality evidence; panel vote 14–1
in favor of combination therapy).
Remark: The quality of the evidence was ini-
tially low given the observational data of the tri-
als supporting combination therapy. The data
were downgraded to very low for two major rea-
sons. First, the results favoring combination
therapy are inconsistent. Although several stud-
ies showed a mortality benefit of combination
therapy, others failed to demonstrate this bene-
fit, and more recent evidence suggests that such
a benefit might be limited to severely ill patients.
Second, although these combination studies
included colistin as potential therapy, not all of
the combination regimens in these studies were
colistin based, making the exact role of poly-
myxin combination therapy difficult to tease out
from other combination regimens.
R28: If a second active agent to which the
infecting CRE displays a susceptible MIC is
unavailable, we recommend that polymyxin B or
colistin be used in combination with a second
and/or third nonsusceptible agent (e.g., a car-
bapenem). Preference should be given to a non-
susceptible agent with the lowest MIC relative to
the respective susceptibility breakpoint (Best
practice recommendation; panel voted 11–4 in
favor of combination therapy).
Evidence Summary. Perhaps the best evidence
supporting polymyxin combination therapy
comes from a series of retrospective observa-
tional studies evaluating outcomes of patients
receiving combination or monotherapy for
bloodstream infections (BSIs) due to carbapene-
mase-producing Enterobacteriaceae (largely,
although not exclusively, producing Kleb-
siella pneumoniae carbapenemase [KPC]).119–122
Two important features of these analyses warrant
comment. First, combination therapy in each of
the studies described in detail here is defined as
agents to which the infecting pathogen is sus-
ceptible according to the MIC. Second, although
most of the combination regimens included a
polymyxin (i.e., colistin), the multivariate mod-
els analyzing “combination therapy” also include
regimens that did not include a polymyxin, and
therefore, in some scenarios, the direct applica-
bility of the findings to the polymyxins remains
unclear. It is also important to note that there is
no adequately powered published RCT to exam-
ine whether therapy with polymyxins (poly-
myxin B or colistin) administered in
combination with another active agent is supe-
rior to polymyxin B or colistin monotherapy
against CRE infections.
Two initial studies suggested a benefit with
combination therapy for CRE BSIs.119, 120
Although limited by small numbers of patients,
both analyses showed dramatic associations
between combination therapy and survival (in-
fection-related mortality of 0/20 [0%] vs 7/15
[47%], p=0.001, and 28-day all-cause mortality
of 2/15 [13%] vs 11/19 [57%], p=0.01, for
patients receiving combination therapy vs
monotherapy, respectively), and the association
of combination regimens with survival
remained significant in a multivariate model
(OR 0.07, 95% CI 0.009–0.71). A report123 on
125 patients with BSI due to KPC-producing
K. pneumoniae furthered these findings because
combination therapy with col-
istin + meropenem + tigecycline was indepen-
dently associated with survival (OR 0.11, 95%
CI 0.02–0.69) when compared with monother-
apy. These findings were further supported in
an analysis by two larger cohort studies,121, 124
one from Greece and the other from Italy,
including patients with infections caused by
carbapenemase-producing Enterobacteriaceae
where receipt of monotherapy (compared with
combination therapy) was associated with an
increased risk of death in the multivariate
model. Of note, these two cohort studies
pointed to a potential advantage of colistin-
meropenem combination therapy when the
meropenem MIC was 8 mg/L or less.121 Inter-
estingly, recent results from the INCREMENT
trial122 that included 437 patients with BSI due
to CRE suggest that the true benefit of combi-
nation therapy might be limited to patients
with a greater severity of illness. In this analy-
sis, combination therapy was associated with
lower mortality compared with monotherapy in
the high-mortality-score stratum (30 [48%] of
63 vs 64 [62%] of 103; aHR 0.56, 95% CI
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0.34–0.91) but not in the low-mortality-score
stratum (17 [24%] of 72 vs 21 [20%] of 105;
aOR 1.21, 95% CI 0.56–2.56, p=0.62). It is
important to note that most patients included
in the studies just cited had BSI.
Based on the available literature, we recom-
mend that when polymyxins are used for the
management of invasive CRE infections, combi-
nation therapy including one or more additional
agents with in vitro activity against the pathogen
should be administered. The rationale for this
recommendation is based on the available obser-
vational evidence suggesting decreased mortality
with combination therapy as well as concerns
regarding emergence of polymyxin resistance
when monotherapy is used. Of note, none of the
previously mentioned studies assessed the
impact of combination regimens on the develop-
ment of polymyxin resistance and were based on
older definitions of meropenem susceptibility
that have now changed to a breakpoint of 2 mg/
L according to EUCAST/CLSI.12, 15
There are few studies which have assessed
the impact of polymyxin combination therapy
with a second nonsusceptible agent on out-
comes in patients with invasive CRE infections.
Perhaps the best evidence suggesting a poten-
tial advantage of this strategy comes from a
recently published RCT comparing colistin
monotherapy versus colistin + meropenem
combination therapy for the management of
carbapenem-resistant gram-negative bacilli.125
In this study, only nine patients (2%) had iso-
lates susceptible (MICs of 8 mg/L or lower) to
meropenem. Both clinical failure and 28-day
mortality occurred in a lower proportion of
patients with CRE receiving the col-
istin + meropenem combination than colistin
monotherapy (failure rates 18/39 [46%] vs 23/
34 [68%]; p=0.19, and 28-day mortality of
21% vs 35%; p=0.24), although statistical sig-
nificance was not demonstrated.125 Based on
the lack of evidence clearly addressing this
issue in CRE and the previously mentioned
concerns/limitations with monotherapy, we rec-
ommend that if no second agents to which the
infecting pathogen displays a susceptible MIC
are available for combination therapy, a second
and/or third “nonsusceptible” agent should be
administered in combination with the poly-
myxin. Given the lack of supporting evidence,
this is a best practice recommendation.
Future Research Needs. Currently a second
ongoing RCT is comparing colistin monotherapy
with colistin + meropenem combination therapy
for the management of invasive infections due to
carbapenem-resistant gram-negative organisms
(https://clinicaltrials.gov/ct2/show/NCT01597973?
term=NCT01597973&rank=1). Data from this
study should further elucidate the role of combi-
nations in the management of CRE. Further-
more, given the potential advantages of
polymyxin B over colistin, clinical data assessing
the impact of polymyxin B–based combination
regimens are needed. Future studies should also
address the impact of infection site on the effec-
tiveness of combination therapy.
XVII. Should Monotherapy or Combination Ther-
apy for Polymyxin B or Colistin Be Used to Treat
Patients with CRAB?
Recommendations. R29: We recommend that for
invasive infections due to CRAB, polymyxin B or
colistin should be used in combination with one
or more additional agents to which the pathogen
displays a susceptible MIC (Best practice recom-
mendation; panel voted 10–5 in favor of combi-
nation).
R30: If a second active agent to which the
infecting CRAB displays a susceptible MIC is
unavailable, we recommend that polymyxin B or
colistin should be used alone as monotherapy
(Weak recommendation, moderate quality evidence;
panel voted 8–7 in favor of monotherapy).
Remark: The quality of the evidence for this
recommendation began as high based on the pre-
viously mentioned RCTs. However, the quality of
the evidence was finally graded as moderate due
to the open-label nature of the RCTs, the use of
nonstudy anti–gram-negative therapies, and rela-
tively low numbers of patients in the rifampin
and fosfomycin studies. The strength of the rec-
ommendation is weak due to the dichotomy in
our panel with regard to optimal management of
these patients, potential bias in the studies, lack
of AFC to optimize polymyxin concentrations,
and dosing concerns in the rifampin trial.
Evidence Summary. Perhaps more than any
other organism mentioned in these guidelines,
the retrospective CRAB literature surrounding
combination therapy versus monotherapy is
nearly uninterpretable due to confounding by
indication, poorly described dosing, and a lack
of clarity regarding the timing of initial adminis-
tration of therapy (and subsequently time to
appropriate therapy) that are incompletely
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described. In addition, the published literature is
often unclear as to whether or not patients had
infection versus colonization because the infec-
tion site is often described as “respiratory” with-
out a clear explanation of how infection was
defined. Also, as previously discussed, given the
complexity of study patients and the lack of a
true definition of infection, the primary end
point of mortality (all-cause, in-hospital, or 30-
day) is suboptimal because often many compet-
ing mortality risks exist. In these studies, it is
not always clear whether death was clearly asso-
ciated with infection.
Therefore, the studies reviewed in this section
are limited to the three major randomized open-
label trials that compared colistin with a second
nonsusceptible agent including rifampin, fos-
fomycin, or meropenem.125–127 Some isolates in
the rifampin and fosfomycin studies were
defined as having in vitro susceptibility to these
agents. However, for the purposes of these
guidelines, the panel considered these isolates to
be nonsusceptible due to a lack of uniform sus-
ceptibility in the isolates included in these stud-
ies (not all isolates were defined as susceptible)
and a lack of dose optimization strategies used
for these agents.126, 127 Taken together with the
insufficient clinical data to support efficacy, con-
cerns for resistance development and the routine
avoidance by clinicians for fosfomycin and
rifampin monotherapy provide a further ratio-
nale as to why both of these agents were consid-
ered nonsusceptible. There are currently no
prospective randomized trials that study poly-
myxin combinations involving a second agent to
which the infecting pathogen displays a suscepti-
ble MIC. Therefore, there are no clinical data
assessing combination therapy with a polymyxin
and a second in vitro active agent, and thus the
best practice recommendation for using this
strategy is an extrapolation from the CRE data.
The three RCTs compared combination with a
nonsusceptible agent versus monotherapy.
The first of the three open-label RCTs com-
paring combinations with monotherapy was a
prospective study126 that enrolled 210 patients
to receive colistin or colistin + rifampin ran-
domly for the treatment of life-threatening XDR
A. baumannii infections. No colistin loading dose
was administered, and the maximum daily main-
tenance dose was low by current standards.
Patients were randomly allocated (1:1) to either
colistin alone, 2 million IU every 8 hours IV, or
colistin plus rifampin 600 mg every 12 hours
IV. The colistin MIC was 0.5 mg/L or lower for
all isolates at randomization. This analysis
reported that the risk of death within 30 days
was similar between combination therapy and
monotherapy (OR = 0.88, 95% CI 0.46–1.69,
p=0.71) despite a significantly improved micro-
biological cure rate in patients receiving col-
istin + rifampin (p=0.034).
Furthermore, no patients developed colistin-
resistant isolates in either arm. This improve-
ment in microbiological cure was consistent
with another small randomized trial (n=43) that
compared colistin and colistin + rifampin, where
time to microbiological clearance was reduced in
the colistin + rifampin arm (3.1 vs 4.5 days;
p=0.029).128 It is important to note that
although rifampin displays potent in vitro syn-
ergy with polymyxins, many suboptimal phar-
macologic characteristics are associated with the
drug. In addition to drug interaction concerns
due to induction of drug metabolism, rifampin
is also associated with adverse drug events
including hepatotoxicity. A nonsignificantly
higher rate of hepatotoxicity in the colistin + ri-
fampin arm was identified in one trial126 (20.8%
in the colistin + rifampin arm vs 11.9% in the
colistin arm; p=0.13). In fact, 10 patients in the
combination therapy arm had rifampin discon-
tinued due to this adverse event. In such an
open-label study, in patients receiving
“monotherapy,” it is difficult to avoid use of
agents that might provide a combinatorial bene-
fit with polymyxins. As an example, ~70% of
patients in the monotherapy and combination
groups received other antibiotics including
agents such as meropenem (prescribed more
commonly in the monotherapy than combina-
tion therapy arm [15.9% vs 3.9%, respectively]).
In another open-label, prospective, random-
ized trial of 94 patients with CRAB infections,
subjects were randomized to receive colistin
alone or colistin + fosfomycin.127 Some patients
in both groups received other antibiotics; for
example, 17.0% and 8.5% of patients in the
monotherapy and combination groups, respec-
tively, received a carbapenem. No significant dif-
ferences were observed between monotherapy
and combination therapy arms in infection-
related (23.1% vs 16.3%; p=0.507) or all-cause
mortality (57.4% vs 46.8%; p=0.41). Interest-
ingly, microbiological cure in the first 72 hours
(65.7% vs 78.8%; p=0.028) and at the end of
treatment (84.5% vs 100%; p=0.023) occurred
more frequently in the combination arm.
Recently, the largest RCT to date (AIDA
study)125 compared colistin monotherapy with
INTERNATIONAL CONSENSUS GUIDELINES FOR THE OPTIMAL USE OF THE POLYMYXINS 29
colistin (9 million IU or 300 mg CBA/
day) + high-dose extended-infusion meropenem
combination therapy for the treatment of car-
bapenem-resistant gram-negative bacilli.
Although this study included CRE and car-
bapenem-resistant P. aeruginosa, 312 of 406
enrolled patients (77%) had CRAB. No signifi-
cant difference was observed in the rate of clini-
cal failure or 28-day mortality between
monotherapy and combination therapy in the
entire cohort (156/198 [79%] vs 152/208 [73%];
p=0.17 for clinical failure, and 43% vs 45%;
p=0.78 for 28-day mortality) or the subset of
patients with A. baumannii infections (125/151
[83%] vs 81%; p=0.64 for clinical failure, and
46% vs 52%; p=0.40 for mortality). A total of
94% of patients in this study had either bac-
teremia or pneumonia with nearly an even split
between the two. Importantly, there was also no
significant difference between groups in the
identification of colistin resistance in clinical
samples by day 28 (6% for monotherapy vs 5%
for combination therapy; p=0.77) or microbio-
logical failure (31% for monotherapy vs 35% for
combination therapy; p=0.49.)
In summary, the data comparing monotherapy
to combination therapy do not support the addi-
tion of that second nonsusceptible agent. There-
fore, the evidence-based recommendation is in
support of monotherapy. There was significant
debate and disagreement among the panel mem-
bers surrounding this recommendation. Many
members of the panel were concerned that even
though the clinical evidence does not support
combination therapy, the PK/PD limitations of
the polymyxins and the development of resis-
tance remain great concerns. The small numbers
and large percentage of patients with pneumonia
in the rifampin and fosfomycin studies as well as
the limitations of the AIDA study (e.g., open
label, the large number of patients treated for
pneumonia, and low Sequential Organ Failure
Assessment scores) are why many panel mem-
bers voted for combination therapy. However,
the final vote was in favor of monotherapy.
Future Research Needs. An ongoing double-blind
RCT will help further shed light on the role of
combinations in the management of gram-nega-
tive infections including those caused by CRAB.
Clinical data assessing the impact of polymyxin
B–based combination regimens are needed.
Future studies should also address the impact of
infection site on the relative effectiveness of
combination therapy versus monotherapy.
XVIII. Should Monotherapy or Combination Ther-
apy for Polymyxin B or Colistin Be Used to Treat
Patients with CRPA?
Recommendations. R31: We recommend that for
invasive infections due to CRPA, polymyxin B or
colistin should be used in combination with one
or more additional agents to which the pathogen
displays a susceptible MIC (Best practice recom-
mendation; panel voted 14–1 in favor of combi-
nation therapy).
R32: If a second active agent to which the
infecting CRPA displays a susceptible MIC is
unavailable, we recommend polymyxin B and
colistin be used in combination with a second
and/or third nonsusceptible agent (e.g., a car-
bapenem). Preference should be given to a non-
susceptible agent with the lowest MIC relative to
the respective susceptibility breakpoint (Best
practice recommendation; panel voted 11–4 in
favor of combination therapy).
Evidence Summary. Very little evidence has
assessed the comparative outcomes of polymyxin
monotherapy and combination therapy for MDR/
XDR P. aeruginosa infections. The primary short-
coming of the available literature is that all of
the analyses are retrospective and observa-
tional, and when analyzed, P. aeruginosa is often
lumped together with other carbapenem-resis-
tant pathogens. Therefore, many of the studies
are difficult to interpret with regard to the
independent impact of polymyxin combination
therapy on P. aeruginosa infection. This section
only includes those analyses that specifically
focused on outcomes in P. aeruginosa infec-
tions.
In a single-center retrospective study of 74
patients with HAP caused by MDR P. aeruginosa
who were treated with polymyxin B, there was
no statistically significant difference in clinical
cure rates between patients receiving polymyxin
B plus another agent (mainly imipenem) and
patients receiving polymyxin B monotherapy
(14/28 [50%] vs 21/46 [46%]; p=0.71).129 In an
additional retrospective single-center study of
258 patients with documented infections (mainly
pneumonia) due to MDR gram-negative organ-
isms, 68 (26.4%) of which were caused by MDR
P. aeruginosa, rates of clinical cure in patients
with P. aeruginosa infection who received col-
istin monotherapy, colistin + meropenem, col-
istin + piperacillin/tazobactam, colistin + ampi-
cillin/sulbactam, and colistin + other agents
were 75.0% (9/12), 85.7% (24/28), 60% (6/10),
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100% (1/1), and 64.7% (11/17), respectively.130
In a retrospective multicenter study, among 89
cancer patients with P. aeruginosa infection
(mainly bacteremia), only 15 were treated with
colistin (17%). Mortality occurred in 3 of 8
patients (37.5%) treated with colistin monother-
apy and 4 of 7 (57.1%) receiving colistin plus
another agent, mostly a b-lactam (p=0.8).131 In
a multicenter retrospective study,132 the authors
compared polymyxin B plus other agents with
polymyxin B monotherapy for treating infections
caused by A. baumannii and P. aeruginosa
(mainly respiratory infections) in 101 critically
ill patients. Most infections were caused by
A. baumannii (83 [82.2%]), and only 18 (17.8%)
were due to P. aeruginosa. Overall, 3 of 18
patients with P. aeruginosa infections received
combination therapy and all survived; 14 of 15
patients treated with polymyxin B monotherapy
died within 30 days (p=0.005).132
The results of a single-center retrospective
cohort of 34 patients with osteoarticular infec-
tions due to MDR P. aeruginosa were reported;
15 (44.1%) had prosthetic joint infections and
19 (55.9%) osteoarthritis. Patients were treated
with IV antibiotics for 6 weeks.133 Combination
therapy (mainly colistin plus a b-lactam) was
associated with higher cure rates than monother-
apy with colistin or a b-lactam (11/15 [73.3%]
vs 6/19 [31.6%], respectively; p=0.016).133
Finally, a single-center prospective study134 was
conducted on 91 patients with infections (most
commonly pneumonia, followed by urinary
tract infection) caused by colistin-susceptible
P. aeruginosa who were treated with colistin. No
association was detected between receipt of
monotherapy or combination therapy and either
clinical failure or mortality.134
The small numbers, discordant results, retro-
spective nature of most studies, and inconsisten-
cies regarding other agents being included in
combination regimens preclude any definitive
conclusion with regard to polymyxin combina-
tion therapy versus monotherapy for P. aerugi-
nosa. Until further evidence becomes available,
the panel recommends that when polymyxins
are used to treat invasive infections caused by
P. aeruginosa that they be used in combination
with one or more additional agents to which the
pathogen displays a susceptible MIC. The ratio-
nale for this recommendation is based on
extrapolation of the available evidence for CRE
and the potential risk of clinical failure or emer-
gence of resistance when monotherapy is used.
If no active agents are available, additional
nonsusceptible agents should be administered
based on MIC value. Preference should be given
to nonsusceptible agents to which the pathogen
demonstrates the lowest MIC respective to the
breakpoint.
Future Research Needs. Additional data, even
observational in nature, assessing outcomes of
polymyxin monotherapy versus combination
therapy for MDR/XDR P. aeruginosa are needed.
Care should be taken by investigators to clearly
describe polymyxin dosing, other antimicrobials
administered, and the degree of susceptibility of
the pathogen to the agents included in the treat-
ment regimens for a given isolate. Future studies
should also address the impact of infection site
on the relative effectiveness of combination ther-
apy.
XIX. Should Inhaled Polymyxins Be Administered
to Patients with HAP/VAP, and If So, Which Agent
Is Preferred?
Recommendations. R33: We recommend that
patients requiring IV polymyxin therapy for sus-
pected or documented XDR gram-negative HAP
or VAP should receive adjunctive polymyxin
aerosol therapy (Weak recommendation, low-qual-
ity evidence).
R34: We recommend that for polymyxin aero-
sol therapy, either colistin or polymyxin B is
appropriate (Weak recommendation; very low-
quality evidence).
Evidence Summary. An RCT was performed
comparing empirical CMS aerosol with placebo
aerosol.135 Patients were randomized to receive
either 4 mL nebulized sterile normal saline or
CMS equivalent to 75 mg colistin base activity
reconstituted in 4 mL nebulized sterile normal
saline that was delivered immediately via a jet or
ultrasonic nebulizer for 10 minutes or until the
nebulized solution container was empty.135 The
regimen and duration of the systemic antibiotic
(s) were chosen by the patient’s responsible
physician. No benefit in clinical cure or mortal-
ity with adjunctive aerosol CMS was demon-
strated in this trial.135 A second RCT has been
performed in 149 critically ill adults who
developed gram-negative VAP.136 Patients were
randomized to receive 4 million IU of aeroso-
lized CMS by nebulisation for 30 minutes three
times/day in addition to IV imipenem 1 g three
times/day compared to IV CMS given as a
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loading dose of 9 million IU followed by 4.5
million IU two times/24 hours in addition to IV
imipenem 1 g three times/day. The clinical cure
rate was 67.1 % in aerosol group and 72% in IV
group (p=0.59). When administered in
monotherapy or in combination, the aerosol
CMS was as effective as IV regimen. Patients in
aerosol group had significantly lower incidence
of acute renal failure.136 In contrast, a 2015
meta-analysis found that clinical response was
improved (OR 1.57, 95% CI 1.14–2.15) and
mortality was lower (OR 0.89, 95% CI 0.51–
1.01) with adjunctive aerosol CMS. All analyses
were imprecise and demonstrated inconsistency
except for microbiological eradication.137 Since
this meta-analysis, only one retrospective cohort
study in pediatric patients has been published
that found essentially the same results for clini-
cal response.138
Most of the studies included in the meta-ana-
lysis focused on MDR pathogens, mainly Pseu-
domonas, Acinetobacter, and CRE.137 Most had
carbapenem-resistant or colistin-only susceptible
isolates. In many cases, polymyxin aerosols were
only added after culture results were known. As
such, early effective empirical antibiotic therapy,
critical for good outcomes in HAP/VAP, may
have been inadequate even in those receiving
polymyxin aerosols.
The assumption is that IV colistin may be
considered in the patients with pneumonia due
to XDR pathogens. Poor results with lower dose
IV therapy and higher nephrotoxicity with high-
dose therapy,139 safety concerns when combina-
tion therapy includes other nephrotoxic agents,
and poor response to polymyxins in preclinical
lung infection murine models all warrant consid-
eration of polymyxin aerosols as an adjunctive
therapy to IV polymyxins. Use of aerosolized
CMS, mainly monotherapy without any IV ther-
apy, for all XDR Pseudomonas and Acinetobacter
VAPs, had equivalent results to IV therapy of
less resistant strains.140 An increase in nephro-
toxicity is difficult to detect in the meta-analy-
sis137 because all studies used IV colistin in
addition to aerosol and used various doses of IV
colistin, but overall nephrotoxicity rates were
high in most studies. More recent studies
including a recent meta-analysis of inhaled CMS
and a retrospective review comparing 95 criti-
cally ill surgical patients who were diagnosed
with A. baumannii VAP support the notion that
nebulized CMS may have less nephrotoxicity
and provide similar clinical results, compared to
IV CMS.141 Interestingly, in a systemic review
the combination of inhaled CMS + IV CMS was
significantly superior to IV CMS for patient sur-
vival and clinical cure for the treatment of resis-
tant A. baumannii pneumonia in critically ill
patients.142, 143 These recommendations place
high value on pharmacologic considerations.
The overwhelming number of case-control
studies, significant clinical experience, and the
RCTs135, 136 have utilized CMS. No direct com-
parison of CMS and polymyxin B has been per-
formed and appear to have equivalent adverse
events, mainly bronchospasm. It is important to
note that it has been suggested that aerosolized
CMS therapy may have a substantial targeting
advantage over IV therapy. Very high concentra-
tions of formed colistin in ELF have been
reported after aerosolized CMS delivery in criti-
cally ill patients. ELF colistin concentrations from
CMS aerosol delivery (9.53 to 1137 mg/L) have
been shown to be much higher than those in
plasma (0.15 to 0.73 mg/L) after intravenous
administration of CMS.146 Typically, 9% of the
CMS dose reaches the alveolar level.146 Colistin
levels achieved in alveolar fluid at the end of an
8-hour interval may be below the MIC of MDR
pathogens, raising the possibility of failure.147
However, colistin was shown to bind to secretory
mucin in sputum or epithelial mucin that lines
airways that may reduce the antibacterial efficacy
of inhaled or IV administered colistin.148 Further-
more, a major concern is the actual aerosol deliv-
ery.149 Experimental studies demonstrated
significant variation in the amount of drug depos-
ited at the alveolar level in mechanically venti-
lated patients.150 A survey found that 30% of
intensivists in Europe and France have used aero-
solized antibiotics at least every other month.151
However, most did not vary ventilator settings to
optimize delivery of the antibiotic to the alveolar
level. Therefore, optimizing ventilator settings
and aerosol generator capabilities likely played a
much greater role in clinical response in studies
in which polymyxin was used.
It is important to acknowledge that ESCMID
has recently published a position paper on the
use of nebulized antibiotics in invasively
mechanically ventilated adults.152 Overall, ESC-
MID’s position paper recommends avoiding the
use of nebulized antibiotics in clinical practice
due to a weak level of evidence regarding their
efficacy and the high potential for underesti-
mated risks of adverse events (particularly, res-
piratory complications). Specifically, ESCMID’s
position paper suggests avoiding the routine
addition of nebulized antibiotics such as colistin,
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to conventional IV antibiotic therapy that
already includes IV colistin for the treatment of
VAP caused by resistant pathogens.
However, the authors of the polymyxin guide-
lines elected to place higher value on the poten-
tial benefit of adjunctive polymyxin aerosol
therapy that outweighed potential risks. These
include placing higher value on data from ran-
domized controlled trials in patients with lower
respiratory tract infections due to XDR gram-
negative bacilli who have been treated with
intravenous polymyxin therapy and have
experienced high rates of mortality and clinical
failure. Preclinical evidence suggests negligible
antimicrobial effect of systemic polymyxins (un-
like aminoglycosides) in lung infection models
although additional clinical studies are urgently
needed to better evaluate this. Therefore,
although there are safety concerns and poor
quality of the evidence with regards to poly-
myxin aerosol therapy, the guidelines committee
believes that the potential benefits outweighs
the risks, which is the basis for the recommen-
dation.
Future Research Needs. Prospective clinical trials
evaluating adjunctive polymyxin aerosol therapy
in addition to IV therapy are necessary. Pharma-
cokinetic and PK/PD studies in lung infection
using aerosol therapy, adjunctive aerosol therapy
in combination with IV polymyxin therapy, and
adjunctive aerosol therapy in combination with
IV polymyxin together with other IV active
antibiotics therapy are necessary. Comparative
studies between aerosol polymyxin B and col-
istin are also needed.
Intrathecal and Intraventricular Administration
of Polymyxins
XX. Should Intraventricular or Intrathecal Admin-
istration of Polymyxins Be Considered in Meningitis
or Ventriculitis?
Recommendations. R35: Intraventricular (IVT)
or intrathecal (ITH) administration of polymyx-
ins at a dosage of 125,000 IU CMS (~4.1 mg
CBA) or 5 mg (50,000 IU) polymyxin B per day
with concomitant IV polymyxin is recommended
for ventriculitis or meningitis caused by MDR
and XDR gram-negative pathogens.
R36: Due to limited experience with poly-
myxin B, CMS is the preferred polymyxin for
intraventricular or intrathecal administration.
Evidence Summary. Health care–associated ven-
triculitis and meningitis are an evolving occur-
rence due to the increasing rates of
neurosurgery procedures. The most prevalent
pathogens are staphylococci and MDR and XDR
gram negatives (A. baumannii, P. aeruginosa, and
K. pneumoniae) depending on local epidemiology
data.153, 154 Therapeutic treatment has become
increasingly challenging due to the increasing
emergence of MDR, and in some cases, colistin
or polymyxin B is the only available antimicro-
bial agent active against meningitis pathogens.155
Colistin exhibits limited penetration into the
cerebrospinal fluid (CSF), with only 5% of
serum colistin levels detected in the CSF after
IV administration.156 In the presence of menin-
gitis, an increase in CSF colistin concentrations
(34–67% of serum colistin levels) was reported
after IV administration, although CSF colistin
levels of only 0.5 mg/L were reported in the set-
ting of meningitis, suggesting potentially sub-
therapeutic colistin CSF concentrations
following IV colistin administration.157 However,
IVT administration of colistin in nine neuro-
surgery patients with XDR gram-negative infec-
tions achieved an estimated average steady-state
concentrations of colistin in the CSF ranging
from 3.0–12.2 mg/L; in the eight patients who
were administered CMS IVT at a dosage of
60,000–125,000 IU (this relates to 1.8–
4.1 mg CBA) per day, trough CSF levels were
between 2.0 and 9.7 mg/L.158 Thus the mea-
sured CSF concentrations in these patients were
continuously above the colistin MIC breakpoint
of 2 mg/L, and clearance of colistin in the CSF
depended on the amount of CSF drained. It is
clear that administration of CMS directly into
the CSF achieves concentrations of colistin that
could not be safely obtained with IV administra-
tion alone. Information is lacking on the CSF
pharmacokinetics of polymyxin B.
Superiority of combined treatment with IV
and IVT colistin treatment with greater potential
for eradication of gram-negative bacilli from CSF
was documented with no evidence of drug accu-
mulation over time.159 Intraventricular poly-
myxin dose is diluted with 3–4 mL of sterile
normal saline and given after removal of an
equal volume of CSF. After polymyxin adminis-
tration, the ventricular drainage is flushed with
2 mL saline solution to minimize the dose
remaining in the drainage and given through an
external ventricular drain that is clamped for
1 hour. Intrathecal polymyxin is adminis-
trated through a lumbar drain.160 The
INTERNATIONAL CONSENSUS GUIDELINES FOR THE OPTIMAL USE OF THE POLYMYXINS 33
recommended daily dose by the European
Medicines Agency and Infectious Diseases Soci-
ety of America (IDSA) for IVT/ITH colistin is
125,000 IU (~4.1 mg CBA),57, 153 whereas for
polymyxin B, 50,000 IU for adults is recom-
mended by the IDSA.153
A systematic review of the evidence regarding
clinical efficacy and safety of IVT or ITH colistin
or polymyxin B was conducted.159–176 A total of
234 cases of gram-negative health care–associated
ventriculitis or meningitis treated with IVT or
ITH colistin or polymyxin B were reported. Intra-
ventricular or ITH colistin was administered in
87% of cases and polymyxin B in the remaining
13%. In most cases (90%), IVT/ITH polymyxins
were administered once/day. Monotherapy with
IVT/ITH polymyxins was given in 24 cases,
whereas in the remaining cases, a variety of par-
enteral antimicrobials (including polymyxins)
was also administered. The median dose of CMS
administered through the IVT or ITH route was
125,000 IU (~4.1 mg CBA) per day, whereas for
polymyxin B, it was 50,000 IU (5 mg) per day
with a mean duration of 18 days. Antimicrobial
therapy was administered via a ventricular drain
in cases of ventriculitis and clamped for 60 min-
utes. Successful outcomes were reported in 85%
of cases: 144 of 167 cases (86%) caused by A. bau-
mannii, 39 of 46 (85%) caused by P. aeruginosa,
and 17 of 21 (81%) caused by K. pneumoniae.
Toxicity was noted in 16 cases (7%), mostly pre-
senting as chemical ventriculitis or meningitis in
two and nine cases, respectively. Seizures were
reported in three cases, numbness of extremities
in two cases, and cauda equina syndrome in
one.159–161
Future Research Needs. Any additional data,
even observational in nature, assessing poly-
myxin IVT and ITH administration are urgently
needed to improve the recommendations in this
section.
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